Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution
- 23 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (20) , 11602-11614
Abstract
A comprehensive understanding of structure–reactivity relationships is critical to the design and optimization of cysteine-targeted covalent inhibitors. Herein, we report glutathione (GSH) reaction rates for N-phenyl acrylamides with varied substitutions at the α- and β-positions of the acrylamide moiety. We find that the GSH reaction rates can generally be understood in terms of the electron donating or withdrawing ability of the substituent. When installed at the β-position, aminomethyl substituents with amine pKa’s > 7 accelerate, while those with pKa’s < 7 slow the rate of GSH addition at pH 7.4, relative to a hydrogen substituent. Although a computational model was able to only approximately capture experimental reactivity trends, our calculations do not support a frequently invoked mechanism of concerted amine/thiol proton transfer and C–S bond formation and instead suggest that protonated aminomethyl functions as an electron-withdrawing group to reduce the barrier for thiolate addition to the acrylamide.Keywords
This publication has 27 references indexed in Scilit:
- Structure-based design of targeted covalent inhibitorsChemical Society Reviews, 2018
- Covalent inhibitors design and discoveryEuropean Journal of Medicinal Chemistry, 2017
- Targeted Covalent Inhibitors for Drug DesignAngewandte Chemie International Edition, 2016
- Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapiesDrug Discovery Today, 2015
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksJournal of Medicinal Chemistry, 2012
- Drug discovery for a new generation of covalent drugsExpert Opinion on Drug Discovery, 2012
- Irreversible Protein Kinase InhibitorsCurrent Medicinal Chemistry, 2011
- The resurgence of covalent drugsNature Reviews Drug Discovery, 2011
- Targeted covalent drugs of the kinase familyCurrent Opinion in Chemical Biology, 2010
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008